Recent Advances in Breast Cancer Treatment

By –  Dr Raman Narang, Consultant Medical & Hemato-Oncologist

Recent advances in breast cancer treatment have expanded the options for selected patients with hormone receptor-positive, HER2-positive and triple-negative disease. Some treatments can lower the risk of recurrence after surgery, while others can help control metastatic cancer after earlier treatment stops working. The relevance of each advance depends on the stage, the pathology report, previous treatment and the patient’s priorities. NCI

Two patients can both be told they have stage II breast cancer and leave their consultations with different plans. One may be advised to have surgery first. Another may be advised to start drug treatment before surgery because the tumour’s response will help guide what comes afterwards.

That distinction matters when a headline announces a new breast cancer drug. The first question I would ask is whether the study included patients with the same stage, subtype and treatment history. Those details determine whether an advance could change the next decision.

1. Which results on my breast cancer report can change treatment?

The core pathology results are ER, PR and HER2. ER and PR tell us whether the tumour expresses hormone receptors. HER2 testing helps identify cancers that may respond to HER2-directed drugs. I interpret these results alongside the tumour size, lymph node involvement, grade and whether the cancer has spread. In early breast cancer, the goal is usually cure. In metastatic breast cancer, treatment generally aims to control the disease, prolong life and preserve quality of life. NCI

The word genetic can also refer to different tests. A germline BRCA1 or BRCA2 test looks for an inherited change and can have implications for both treatment and relatives. A tumour biomarker test looks for features of the cancer that may guide a drug choice. A gene-expression assay, in selected early hormone receptor-positive, HER2-negative cancers, can help estimate whether chemotherapy would add enough benefit to endocrine therapy. Ask what decision a test could change before paying for it. NCI

2. What is new for hormone receptor-positive breast cancer?

Endocrine therapy remains central for hormone receptor-positive breast cancer. In selected patients with higher-risk early-stage, HER2-negative disease, adding a CDK4/6 inhibitor can lower the risk of an invasive recurrence. The NATALEE trial supported the addition of ribociclib to an aromatase inhibitor in eligible patients with stage II or III disease. Abemaciclib is another option in defined higher-risk settings. The choice depends on eligibility, the expected absolute benefit, side effects and the ability to complete treatment and monitoring. FDA

For some patients with high-risk, HER2-negative early breast cancer and an inherited BRCA1 or BRCA2 pathogenic variant, olaparib after chemotherapy is another advance. The OlympiA trial showed a survival benefit in the population it studied. Where someone qualifies for more than one postoperative treatment, the order and the strength of evidence for each option deserve an explicit discussion. NCI

In advanced ER-positive, HER2-negative disease, a change called ESR1 can help guide the choice of the next endocrine-based treatment after progression. One recent example is the May 2026 U.S. approval of vepdegestrant for eligible patients with an ESR1 mutation after at least one line of endocrine therapy. The practical question is whether testing for ESR1 would change the treatment you can receive next. FDA

3. How have treatment options changed for HER2-positive and HER2-low breast cancer?

One major development is the wider use of antibody–drug conjugates, or ADCs. These drugs link an antibody that recognises a target on the cancer cell to a cell-killing drug. Trastuzumab deruxtecan, also called T-DXd, is a HER2-directed ADC whose role now spans several distinct treatment settings. FDA

  • HER2-positive advanced breast cancer. In December 2025, the U.S. FDA approved T-DXd with pertuzumab as first-line treatment for eligible adults with unresectable or metastatic HER2-positive disease. FDA
  • HER2-positive early breast cancer. In May 2026, the U.S. FDA approved two distinct uses. One is part of a specific regimen before surgery for stage II–III disease. The other is after surgery when invasive cancer remains following specified preoperative treatment. FDA
  • Hormone receptor-positive, HER2-low or HER2-ultralow advanced breast cancer. A separate U.S. indication covers eligible patients whose cancer has progressed after endocrine therapy in the metastatic setting. In DESTINY-Breast06, T-DXd delayed progression compared with the chemotherapy options studied. The exact HER2 staining result matters for this decision. FDA

T-DXd can cause lung inflammation, also called pneumonitis or interstitial lung disease. A patient starting it should know whom to contact promptly for a new cough, breathlessness or fever. For patients seeking breast cancer treatment in Delhi, international evidence is one part of the decision. The exact Indian indication, access, expected out-of-pocket cost and ability to monitor treatment should be confirmed locally. The approval examples above describe U.S. regulatory decisions. accessdata.fda.gov

4. Who can benefit from immunotherapy for triple-negative breast cancer?

For eligible patients with high-risk early triple-negative breast cancer, the KEYNOTE-522 regimen gives pembrolizumab with chemotherapy before surgery and continues pembrolizumab afterwards. The trial showed an overall survival benefit. Eligibility for this early-stage approach does not require a positive PD-L1 result. The benefit should be weighed against immune-related side effects and the patient’s other medical conditions. NCI

In unresectable locally advanced or metastatic triple-negative breast cancer, PD-L1 can change the first-line plan. In June 2026, the U.S. FDA approved sacituzumab govitecan, an ADC, with pembrolizumab for eligible adults whose tumours have a PD-L1 combined positive score of at least 10. The supporting trial showed longer time before progression with the ADC combination than with chemotherapy plus pembrolizumab. The final overall survival analysis was still pending at approval. FDA

5. How do I know whether a recent advance applies to me?

What I look for clinically

I start with the decision in front of us. Do we need to choose between surgery and treatment first? Are we trying to reduce recurrence risk after surgery? Has metastatic disease grown despite the current treatment? I then check how closely the patient matches the population that benefited, what outcome actually improved, and what taking the treatment would involve in everyday life. For a postoperative decision, I try to explain the absolute reduction in recurrence risk where it can reasonably be estimated. In metastatic disease, I also ask what the patient most wants to preserve, whether that is independence, symptom control or time away from hospital.

An if–then map for your next appointment

If this is your situationThen ask your team
You have newly diagnosed stage II–III HER2-positive or triple-negative breast cancerWould treatment before surgery help guide what I receive afterwards?
You have early HR-positive, HER2-negative breast cancer after surgeryWhat is my recurrence risk, and would a gene-expression assay or an additional drug change the plan?
Invasive cancer remains after preoperative treatmentHow does the remaining disease change my postoperative options for this subtype?
Metastatic breast cancer has progressedWould reviewing the pathology, repeating a biopsy or ordering a specific biomarker test change the next treatment?

The map is a starting point for discussion. Individual recommendations depend on the full clinical and pathology record. NCI

Patient checklist

  • Bring your biopsy report and, if available, the slides or tissue block details.
  • Bring your ER, PR and HER2 results, including the actual HER2 score and any confirmatory ISH report.
  • Carry relevant scans and any operative or final surgical pathology report.
  • List previous cancer medicines, approximate dates and significant side effects.
  • Note close relatives with breast, ovarian, pancreatic or prostate cancer and their ages at diagnosis, if known.
  • Ask what each proposed test could change and when the result is needed.
  • Ask for the treatment goal, expected benefit, monitoring plan and estimated costs in writing.

Frequently asked questions

Can newer drugs help me avoid chemotherapy?
Sometimes. Some patients with early hormone receptor-positive cancer can avoid chemotherapy after an appropriate risk assessment. In other settings, chemotherapy remains part of a curative regimen or is combined with a newer drug. NCI

Is HER2-low the same as HER2-positive?
No. HER2-low describes a lower level of HER2 staining. It can help identify candidates for certain ADCs in advanced disease. HER2-positive disease has a different set of treatment options. FDA

Does every patient need broad genomic testing?
Testing should answer a specific question. For some early cancers, standard pathology provides enough information for the next decision. Selected patients may benefit from inherited-risk testing, a gene-expression assay or a tumour biomarker test. NCI

Does a U.S. FDA approval mean I can receive the same treatment in India?
Ask your treating team to confirm the Indian indication for your exact situation, local availability, affordability and monitoring requirements before making a decision.

Related reads

Closing perspective

A recent advance matters when it changes a decision you face now. If you have been given different recommendations about surgery first, treatment before surgery, or what to do after a new biomarker result, a second opinion on your cancer treatment plan can help clarify where the recommendations differ and which evidence applies to your case.

This article is for general education. Please discuss individual testing and treatment decisions with your treating oncology team.

References for editorial review

  • National Cancer Institute. Breast Cancer Treatment (PDQ®), Health Professional Version. NCI
  • ASCO. Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I–III Breast Cancer, living guideline, version 2026.1.0. ascopubs.org
  • Schmid P, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. KEYNOTE-522, NEJM, 2024. nejm.org
  • Bardia A, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. DESTINY-Breast06, NEJM, 2024. icm.unicancer.fr
  • U.S. FDA oncology approval notices and labels for T-DXd in HER2-positive and HR-positive HER2-low or ultralow breast cancer, and for first-line sacituzumab govitecan in advanced triple-negative breast cancer. FDA

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top